medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Mass molecular testing for COVID19 using NGS-based technology and
a highly scalable workflow
Fernanda de Mello Malta1*, Deyvid Amgarten1*, Felipe Camilo Val1, Rubia Anita Ferraz
Santana1, Murilo Castro Cervato1, Bruna Mascaro Cordeiro de Azevedo1, Marcela de
Souza Basqueira1, Camila Oliveira dos Santos Alves1, Maria Soares Nobrega1, JoÃ£o
Renato Rebello Pinho1Â¥
1

LaboratÃ³rio de TÃ©cnicas Especiais, Hospital Israelita Albert Einstein, SÃ£o Paulo, Brazil
Authors contributed equally to this work
Â¥
Address for correspondence: JoÃ£o Renato Rebello Pinho, Laboratorio de TÃ©cnicas
Especiais, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627/701 05651-901
Phone +55112151-2530 SÃ£o Paulo-SP Brazil email: joao.pinho@einstein.br
*

ABSTRACT
Since first reported case of the new coronavirus infection in Wuhan, China, researchers
and governments have witnessed an unseen rise in the number of cases. Thanks to the
rapid work of Chinese scientists, the pathogen now called SARS-CoV-2 has been
identified and its whole genome has been deposited in public databases by early January
2020. The availability of the genome has allowed researchers to develop Reverse
Transcription - Polymerase Chain Reaction (RT-PCR) assays, which are now the goldstandard for molecular diagnosis of the respiratory syndrome COVID19. Because of the
rising number of cases and rapid spreading, the world has been facing a shortage of RTPCR supplies, especially the ones involved in RNA extraction. This has been a major
bottleneck to increase testing capacity in many countries that do not significantly
manufacture these supplies (Brazil included). Additionally, RT-PCR scalability is highly
dependent on equipment that usually perform testing of 96 samples at a time. In this work,
we describe a cost-effective molecular NGS-based test for diagnosis of COVID19, which
uses a single-step RNA extraction and presents high scalability and accuracy when
compared to the gold-standard RT-PCR. A single run of the NGS-based test using the
Illumina NextSeq 550 mid-end sequencing equipment is able to multiplex 1,536 patientâ€™s
samples, providing individual semi-qualitative results (detected, not detected). Detected
results are provided with fragments per million (FPM) values, which was demonstrated
to correlate with RT-PCR Cycle Threshold (CT) values. Besides, usage of the high-end
Illumina Novaseq platform may yield diagnostic for up to 6,144 samples in a single run.
Performance results when compared with RT-PCR show general accuracy of 96% (or
98% when only samples with CT values for gene N lower than 30 are considered). We
have also developed an online platform, called VarsVIDÂ®, a VarstationÂ® feature, to help
test executors to easily scale testing numbers. Sample registering, wet-lab worksheets,
sample sheet for sequencing and resultsâ€™ display are all features provided by VarsVIDÂ®
on VarstationÂ®. Altogether, these results will contribute to control COVID19 pandemics.
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1. Introduction
In December 2019, it was reported in Wuhan City, Hubei province in China, cases of
pneumonia of unknown etiology. In 7th January 2020, the causative agent was identified
from throat swab samples in a study conducted by the Chinese Center for Disease Control
and Prevention (CCDC) (1). The new coronavirus was provisionally named 2019 novel
coronavirus (2019-nCoV) (2) (3). Coronaviruses, from the family Coronaviridae, are
enveloped single-strand RNA viruses with genomes ranging from 26 to 32 kilobases in
size. Most members of the coronaviruses family have similar genome organization and
expression, usually composed by ten or more nonstructural proteins (nsp proteins) and by
the structural proteins spike (S), envelope (E), membrane (M), and nucleocapsid (N) (3).
Through Next-Generation Sequencing technology (NGS), the virus complete genome
was described and phylogenetically classified as belonging to the genus betacoronavirus.
Thereafter, 2019-nCOV was named SARS-CoV-2 (1, 4).
On March 2020, the WHO (World Health Organization) declared COVID-19 as
pandemic (5) and have issued guidelines about clinical and epidemiological findings,
stating that extensive laboratory tests should be performed (6). Since then, there has been
a robust scientific response and a global search for the best diagnostic tool to identify
patients infected by SARS-CoV-2. Several laboratory methods have been used to detect
the etiological agent of this respiratory syndrome, as for instance enzyme-linked
immunosorbent assay and nucleic acid hybridization. Moreover, early publication of
SARS-CoV-2 genome has allowed development of molecular tests based on reverse
transcription polymerase chain reaction, widely known as RT-PCR. Months into the
pandemics now, RT-PCR has been the gold standard technique for molecular
identification of the virus and for diagnosis of COVID19.
NGS technology have revolutionized the genomics field and have been providing
a novel and effective way to screen samples and detect pathogens. In association with
bioinformatics tools, this technology is changing the way as research and diagnostic
centers can respond to infectious disease outbreaks. This progress is paving the way for
new approaches and for improving our knowledge about the disease origin, occurrence
and transmission, through a large-scale genomic approach. Over 16,000 SARS-CoV-2
genome sequences have been deposited in public repositories until May 2020, and
genome sequencing is helping researchers to understand SARS-CoV-2 haplotypes
distribution, mutations and phylogeny (7-9).
In a pandemic scenario, it is essential to carry out population mass testing to
prevent rapid spread of the infection and to minimize mortality rates. In response to this
need, we have developed an NGS-based diagnostic test for the new coronavirus, which
presents 96% of accuracy in paired analyses with the RT-PCR gold standard. Our NGSbased test is highly scalable, having the ability to perform up to 1,536 samples
simultaneously on a mid-end NextSeq 550 Illumina sequencing equipment. This number
is 16 times more than what is done today by the gold standard RT-PCR technique and it
may be even more expanded considering the use of a high-end Novaseq 6000 Illumina
equipment (3072 to 6144 samples in a single run). This new technology expands the
global diagnostic capacity, enabling rapid initiation of treatment and isolation of the
infected, altogether contributing to control COVID19 pandemics.
2

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

2. Methods
2.1.General workflow
We have developed a complete workflow to execute the NGS-based testing, including
wet-lab and bioinformatics analyses, as shown in Figure 1. This workflow is highly
scalable in order to avoid bottlenecks and to increase testing capacity. Wet-lab steps may
be automated by pipetting robots, and bioinformatics analyses may be performed by a
very time and cost-efficient pipeline implemented through VarsVIDÂ® on VarstationÂ®
online platform.

Figure 1: Panoramic view of the COVID19 NGS-based test reported in this work.
2.2. Samples and previous results
A total of 269 samples with previous results for COVID19 qRT-PCR were deidentified
and selected from routine testing at the Laboratorio de Tecnicas Especiais (LATE),
Hospital Israelita Albert Einstein (SÃ£o Paulo, Brazil). qRT-PCR routine assays were
performed using XGEN MASTER COVID-19 kit (Mobius Life Science), which uses a
protocol for amplification of fragments of the genes N and ORF1ab. From the 269
samples, 112 tested positive for SARS-CoV-2 with CTs values for gene N ranging from
13 to 35.24. Remaining 157 samples tested negative. We have also included negative
plaque-controls with nuclease-free water to assess cross-contamination among plaques or
other sequencing artefacts. Finally, AMPLIRUN Coronavirus RNA quantified
commercial SARS-CoV-2 control (Vircell Microbiologists, Spain) was serially diluted
and tested for assessing limit of detection (LoD). Clinical samples presented in this work
were used according to approval of the Hospital Ethical Committee under report
#4.178.076.

3

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

2.3. RNA extractions and internal controls
Total RNA was extracted using the QuickExtract DNA Extraction Solution (Lucigen, WI,
USA) according to the manufacturerÂ´s instructions. MS2 phage RNA spike-in was added
after extraction to function as an additional routine internal control of true negative
samples, i.e., negative samples that do not yield MS2 sequences after bioinformatics
analyses will be automatically placed for repetition.
2.4. Amplicon generation by RT-PCR
RT-PCR reactions for individual patient samples were performed using SuperScriptâ„¢ III
One-Step RT-PCR (Invitrogen) with a combination of multiplex primers designed to
amplify highly conserved regions of SARS-CoV-2 and MS2 control genomes. Several
target and control primers were tested for efficiency and multiplex compatibility and
sequences are subject to intellectual property. Assays were carried out following standard
protocols recommended for the kit: 11 ÂµL template RNA, 2 ÂµL SuperScriptâ„¢ III
RT/Platinumâ„¢ Taq Mix (Thermo Fisher Scientific, Waltham, MA), 25 ÂµL 2X Reaction
Mix (Thermo Fisher Scientific, Waltham, MA), 1 ÂµL of each primer 10 ÂµM (multiplex
primer 1 forward, multiplex primer 1 reverse, multiplex primer 2 forward, multiplex
primer 2 reverse), 0.5 ÂµL of internal control primer forward 10 ÂµM, 0.5 ÂµL of internal
control primer reverse 10 ÂµM and 7 ÂµL nuclease-free water for a final reaction volume
of 50 ÂµL. The RT-PCR reactions were incubated using the following cycling conditions:
56Â°C for 15 minutes, followed by one cycle of 94Â°C for 2 minutes, followed by 40 cycles
of 94Â°C for 15 seconds, 65Â°C for 30 seconds and 72Â°C for 5 seconds and followed by one
cycle of 72Â°C for 5 minutes.
2.5. Library generation
Each patientâ€™s set of individually amplified fragments for SARS-CoV-2 and MS2
genomes was combined in a pool using the Biomek FX Automation (Beckman Coulter).
After pool combination, libraries were built using KAPA HiFi Hot Start Enzyme (Roche)
and Illumina Nextera XT v2 Index kit set A/B/C/D (Illumina, San Diego, CA, United
States). Reaction was carried out with 5 ÂµL cDNA, 25 ÂµL KAPA HiFi Hot Start Enzyme,
5 ÂµL Index i5, 5 ÂµL Index i7, 10 ÂµL nuclease-free water for a final reaction volume of 50
ÂµL. The following cycles were used for the PCR reactions: 95Â°C for 3 minutes, followed
by 8 cycles of 95Â°C for 30 seconds, 55Â°C for 30 seconds and 72Â°C for 5 minutes and
followed by one cycle of 72Â°C for 5 minutes.
2.6. Library purification and normalization
Library purification were performed in the Biomek FX Automation (Beckman Coulter)
using Agencourt AMPure XP Beads (Beckman CoulterÂ®) following standard protocols.
For normalization, all libraries were quantified by Qubit Fluorometer using Qubitâ„¢
dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA) and size assessment was
performed on Agilent 2200 TapeStation system for a dilution of 4nM. Each 4nM pool
was combined into one pool and submitted to sequencing.

4

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

2.7. Sequencing
Sample pools were diluted to 2 nM based on the Qiaseq Library Quant Assay Kit (Qiagen)
measurements and the size information was performed on Agilent 2200 TapeStation
system. For the pool denaturation, 10 ÂµL of the 2 nM pool was added with 10 ÂµL of 0.2
N NaOH, after 10uL de Tris-HCl pH7 200mM was added to stop the denaturation
process. 970 ÂµL of Illuminaâ€™s HT1 buffer was add to the pool for dilute it to 20 pM and
after 117uL of 20 pM pool was add to 1.183uL of Illuminaâ€™s HT1 buffer to dilute it to 1.8
pM. Diluted pool was spiked with 15% PhiX and sequenced using a Nextseq 500/550
Mid Reagent Cartridge v2 300 cycles (Illumina, San Diego, CA).
2.8. Analyses
Sequencing results were analyzed by a pipeline developed specifically for this highly
scalable assay, which performs the general steps of (1) First demultiplexing (2) Quality
Control, (3) Mapping to references (4) Assessing reads aligned to targets and (5) Second
demultiplexing to generate patientâ€™s individual qualitative results. More specifically, raw
sequencing data is demultiplexed using Illuminaâ€™s tool blc2fastq with barcode
mismatches set to 0 and other parameters set to default. Quality control is performed by
cutadapt filtering to size (>50bp), average quality (Qp > 20) and using trimming options
to remove NextSeqâ€™s biased low-quality ends. Mapping to references were carried out
using bwa-mem tool (default parameters) with SARS-CoV-2 isolate Wuhan-Hu-1
(NC_045512.2) and Phage MS2 (NC_001417.2) as pathogen reference and internal
control spike-in, respectively. Reads aligned to target were assessed using Bedtools and
qualitative results were generated based on a threshold of reads (â‰¥ 10) and on the decisiontable shown in Table 1. A quantitative value was calculated for each positive viral target
based on abundance of reads. This metric was termed Fragments per Million (FPM) and
is related to similar metrics used in the scientific community for NGS analyses (FPKM,
RPKM, etc.). An additional normalization for amplicon length was not necessary,
considering that all amplicons were designed to have the same size. FPM values were
compared with CT values and Pearson correlation coefficient was calculated. FPM is
calculated as follows:

ğ¹ğ‘ƒğ‘€ =

ğ‘Ÿğ‘’ğ‘ğ‘‘ğ‘ _ğ‘ğ‘™ğ‘–ğ‘”ğ‘›ğ‘’ğ‘‘_ğ‘¡ğ‘ğ‘Ÿğ‘”ğ‘’ğ‘¡
. 106
ğ‘ğ‘ğ‘ ğ‘ ğ‘’ğ‘‘_ğ‘„ğ¶_ğ‘Ÿğ‘’ğ‘ğ‘‘ğ‘ 

5

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1: Decision table based on bioinformatics outputs to generate a patientâ€™s individual
qualitative result. Each control or target is considered positive (+) if count of sequences
is higher than a selected threshold. Routines samples are placed to repetition when no
internal control or target sequences are generated.
Result
Detected
Detected
Detected
Detected
Not detected
Repeat

Control
+
+
+
+
-

Viral target 1
+
+
+
-

Viral target 2
+
+
+
-

3. Results and Discussion
3.1. Performance results
In this work, we show a new amplicon-based methodology to amplify highly conserved
regions of the SARS-CoV-2 genome and to identify these fragments using NGS
sequencing. A total of 269 clinical samples with previous results for COVID19 RT-PCR
were tested and performance results are summarized as follows. From 112 samples which
were SARS-Cov-2 positive in RT-PCR, 102 were confirmed by NGS. From 157 samples
RT-PCR that tested negative, NGS results confirmed 156. These numbers show that the
NGS-based technique has overall accuracy of 95.9%, with 91.1% and 99.4% of sensitivity
and specificity, respectively. Based on these results we also calculated the positive
predictive value (PPV) and the negative predictive value (NPV). PPV value was 99%
(102 NGS true positive and 1 NGS false positive) and NPV value was 94% (156 true
negatives and 10 false negatives) (Figure 2). We noted that most false negative results
presented RT-PCR CT values higher than 30 (6 false negatives). Sensitivity and
specificity for samples with CT values lower than 30 were 96.1% and 99.4%,
respectively. Accuracy for samples with CT values lower than 30 hitched 98,1% (Figure
2). Average SARS-CoV-2 target NGS coverage for positive samples was 25,172x.

6

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Test Performance for all CTs
100,0%

95,9%

99,4%

99,0%

91,1%

Test Performance for CTs lower than 30
94,0%

100,0%

75,0%

75,0%

50,0%

50,0%

25,0%

25,0%

0,0%

98,1%

96,1%

99,4%

99,0%

97,5%

PPV

NPV

0,0%
Accuracy Sensitivity Specificity

PPV

NPV

Accuracy Sensitivity Specificity

Figure 2: Accuracy, sensitivity, specificity, PPV and NPV percent of SARS-CoV-2 NGS
based tested for all samples and for samples with gene N CT values lower than 30.

Positive samples presented average FPM of 2.14 x 105, while average CT for gene N
was 24.4. Pearson correlation coefficient between values of CT and FPM was PCC=-0.89
(p-value < 0.001), suggesting that FPM may very well reflect CT values. FPM values of
the quantified spike-in controls presented low variance among samples tested, averaging
1.42 x 108 with standard deviation of Â± 0.58 x 108. Therefore, we propose this new metric
to be associated with qualitative NGS results in the same way as CT values are associated
with RT-PCR. FPM values may provide patient and physician an important semiquantitative idea of viral loads to guide clinical responses. It is important to note, though,
that FPM values may vary according to the viral target (Spike, N, Matrix, etc.) and that
one target may be more sensitive than others as occurs with RT-PCR.
NGS testing of the AMPLIRUN Coronavirus RNA quantified commercial SARSCoV-2 control (Vircell Microbiologists, Spain), shows that dilutions from 1 x 103
copies/mL to 1 x 105 copies/mL were successfully identified in replicates by the technique
presented in this work. Therefore, we defined 1 x 103 copies/mL as the limit of detection.

3.2.Automation and user-friendly results using the VarsVIDÂ® platform
As this test was intended to process thousands of samples per run, we anticipated an
enormous struggle to organize and perform wet-lab assays. To address this potential
bottleneck, we have developed an online platform called VarsVIDÂ® to automate the
entire process of sample registrations and generation of worksheets. Partner laboratories
using VarsVIDÂ® will only need to provide a csv file with sample relevant information in
order to plan a run and generate worksheets. These worksheets were intended to help the
wet-lab professional and to avoid planning mistakes. VarsVIDÂ® will also provide a
SampleSheet for Illumina sequencing, so that the professional will not waste unnecessary
time registering hundreds of libraries in the basespace platform.
Bioinformatics analyses may also be performed using the VarsVIDÂ® platform, which
was planned to be cloud-based and highly elastic according to laboratory requirements.
These efforts resulted in the analyses of hundreds of samples FASTQs in a matter of
7

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

minutes. Finally, VarsVIDÂ® provides user-friendly online results in a dash board, as well
as the possibility of generating csv files for further processing.

4. Conclusion
While there is a global struggle to control the SARS-CoV-2 pandemic, it is fundamental
that new diagnostic methodologies that allows mass testing are made available. Our test
was developed considering the best way to guarantee access to accurate molecular
diagnosis, without compelling to bottle-necks of supplies such as RNA extraction kits.
This proposed methodology uses simple, inexpensive and commonly available reagents
for extraction and PCR. Moreover, NGS sequencing costs are extremely diluted when
considering the high capacity for sample multiplexing. Finally, VarsVIDÂ® platform
facilitates the managements of many samples, execution of complex tasks and inspections
of results. Altogether, this newly developed NGS-based test is able to detect SARS-CoV2 with high accuracy, higher scale and lower costs when compared with RT-PCR. We
expect that NGS-based testing for COVID19 will multiply worldâ€™s capacity of detecting
SARS-CoV-2 and fighting this pandemic.

Acknowledgements
We thank Dr Cristovao Mangueira and the technical staff of Laboratorio de Tecnicas
Especiais, Hospital Israelita Albert Einstein, for scientific and technical support.

Author contributions
FMM, DA, FCV and MCC conceived and planned this study. BMCA, MSB, COSA,
MSN and FMM conducted wet-lab validation. DA and MCC conducted bioinformatics
analyses. RAS and JRRP guided and provided insights to the development of this test.
All authors have read and contributed to this manuscript.

References
1.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
2.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
Lancet. 2020;395(10224):565-74.
3.
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic
Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016;24(6):490-502.
4.
Coronaviridae Study Group of the International Committee on Taxonomy of V. The
species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and
naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44.
8

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20172106; this version posted August 11, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

5.
Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health
Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19).
Int J Surg. 2020;76:71-6.
6.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
JAMA. 2020.
7.
Lake MA. What we know so far: COVID-19 current clinical knowledge and research.
Clin Med (Lond). 2020;20(2):124-7.
8.
Nextstrain. Genomic epidemiology of novel coronavirus - Global subsampling
[Available from: https://nextstrain.org/ncov/global.
9.
Gohl DM, Garbe J, Grady P, Daniel J, Watson RHB, Auch B, et al. A Rapid, CostEffective Tailed Amplicon Method for Sequencing SARS-CoV-2. biorxiv. 2020.

9

